Peter S. Hammerman
Forma Therapeutics (United States)
ORCID: 0009-0006-9143-899XAlso affiliated with Casma Therapeutics (United States)
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 9 papers. Top paper: “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W”.
Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell +17 more
Andrew Portell, Elena V. Ivanova, Patrick H. Lizotte, Navin R. Mahadevan, Jonathan Greene +23 more
Marc Ladanyi, William Lee, David G. Beer, Bryan Hernandez, David J. Kwiatkowski +27 more
Filippos Kottakis, Yvonne Y. Li, Rahul Karnik, Peter S. Hammerman, Alexander Meissner +14 more
Jacob B. Reibel, Jeremy H. Tchaicha, Julián Carretero, Pasi A. Jänne, Mohit Butaney +22 more
Jeremy H. Tchaicha, Andrey Sivachenko, Kwok‐Kin Wong, Qingsong Liu, Ellen M. Beauchamp +11 more
Vonn Walter, Joel S. Parker, Melissa A. Troester, Peter S. Hammerman, Charles M. Perou +6 more
Grit S. Herter-Sprie, Xiaoen Wang, Kwok‐Kin Wong, Carla F. Kim, Anil K. Rustgi +29 more
Julián Carretero, Roderick T. Bronson, James E. Bradner, Charles Y. Lin, Myles Brown +26 more